News

A 12-week intervention combining breathing exercises, cold exposure, and meditation — known as the Wim Hof Method (WHM) — or a lifestyle intervention aimed at improving physical activity and dietary habits may help reduce inflammation linked to disease progression in people with multiple sclerosis (MS), a pilot study suggests.

In multiple sclerosis (MS), certain disease-driving immune cells carry a protein marker called CD29, which helps them move into the brain and trigger inflammation. That is the key finding of a new study by researchers in the Netherlands, who zeroed in on the protein as a driver of MS.

The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multiple sclerosis (MS). Optic neuritis, marked by inflammation of the optic nerve that carries signals between the eyes and the brain, can…

A new model of nerve fibers may serve as a platform to screen for experimental treatments that can promote myelin repair in multiple sclerosis (MS), a study showed. The model is made of soft micropillars around which myelin-producing cells can wrap myelin. Researchers found that some drugs tended to…

Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase 2 clinical trial of Lucid-MS, a “first-in-class” oral therapy designed to halt the progression of multiple sclerosis (MS) by protecting myelin, or the protective sheath around nerves in…

MS Canada is inviting cyclists across the country to take part in its 2026 MS Bike season, a series of fundraising rides aimed at supporting Canadians living with multiple sclerosis (MS). The annual MS Bike series brings together thousands of participants to ride scenic routes while raising money…

The cells that line the inside of the gut — known as intestinal epithelial cells — may play a key role in triggering inflammation that drives multiple sclerosis (MS), a study showed. The study found that these cells can activate a type of T-cell known as Th17 cells. These…

More than 70% of people with multiple sclerosis (MS) receiving outpatient rehabilitation take at least five medications — often including vitamin supplements and drugs used to manage symptoms such as muscle stiffness, pain, and mental health issues — to treat their MS. That’s according to a real-world study in…

A new study being funded by the National Multiple Sclerosis Society (NMSS) will seek to better understand how women with multiple sclerosis (MS) navigate menopause and develop resources to address gaps in care. The study, “The Menopausal Transition, MS Symptom Management, and Multidisciplinary Care Gaps,” will use input from…

Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims to slow myelin loss — which ultimately results in the neurological problems that drive multiple sclerosis (MS) — in people with the progressive…

Multiple sclerosis (MS) has become far more common in England over the past two decades, but people diagnosed more recently are living longer, according to a study led by University College London (UCL). The shift reflects major advances in MS diagnosis and care. But researchers found that social…

Variations in the activity of a protein called p21 may underlie the differences in the activity of myelin-repairing cells in the brains of people with multiple sclerosis (MS), according to a new study. The findings may help to explain why different people with MS develop different forms of…

Exercises to strengthen the respiratory muscles — the muscles in the chest needed to move air in and out of the lungs when breathing — can help improve lung function in people with multiple sclerosis (MS), according to a new analysis. This type of exercise, known as respiratory muscle…

IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was well tolerated in healthy volunteers when given at single increasing doses. The findings come from the single-ascending dose portion of an ongoing Phase 1 clinical trial (NCT06637865), which tested…

An experimental therapy designed to eliminate harmful B-cells — key drivers of inflammation in multiple sclerosis (MS) and other autoimmune diseases — has reached an early development milestone. The treatment candidate, CDR111, is being developed under a collaboration between CDR-Life and Boehringer Ingelheim. The milestone was achieved…

When Brenda Snow started experiencing vertigo, vision problems, and other symptoms in the early 1990s, she visited several doctors. However, as often happens with complex conditions, she struggled to have her concerns validated. Snow, who lived in Northern California at the time, didn’t give up. She continued looking for answers…

The Accelerated Cure Project for Multiple Sclerosis (ACP) has received funding to help interpret and share findings from the DISCO-MS study, which examined whether older adults with stable multiple sclerosis (MS) could stop disease-modifying medications, to support more informed treatment decisions. The award comes through the Eugene Washington…

Brain atrophy, or the loss of brain volume, in people with relapsing-remitting multiple sclerosis (RRMS) appears to slow with age, according to data from more than 4,000 patients who took part in Phase 3 clinical trials. Researchers found that older adults with RRMS had significantly smaller brain volumes than…

Ludwig Kappos, MD, a neurologist and researcher at University Hospital in Basel, Switzerland, has been named the 2026 recipient of the John Dystel Prize for Multiple Sclerosis Research for his central role in advancing understanding and treatment of multiple sclerosis (MS) and monitoring of disease progression. The $40,000…

A combination of drugs widely used in anti-aging studies seems to compromise the function of the brain’s myelin-making cells and cause profound myelin loss, according to the findings of a new study in mice and lab-grown cells. The dual treatment, which combines dasatinib and quercetin, also known as D+Q, caused…

Close relatives of people with multiple sclerosis (MS) are 100 times more likely to develop the neurological disorder than the general population, according to a new analysis of GEMS data. Among participants in GEMS, a large-scale observational study assessing MS risk among family members, about half said…

The National Multiple Sclerosis Society has designated UC Davis Health in California as a new Center for Comprehensive MS Care, recognizing its ability to provide coordinated, multidisciplinary care for people with multiple sclerosis (MS). The designation is part of the society’s Network of MS Healthcare Professionals, which…

Innocare Pharma has dosed the first healthy volunteer in a clinical trial in China testing ICP-538, its oral treatment candidate for multiple sclerosis (MS) and other autoimmune diseases. The novel experimental therapy works by promoting the degradation of the VAV1 protein, essential for the function of T-cells and…

People with multiple sclerosis (MS) who experience their first symptoms after age 50 tend to have faster disability progression than those with earlier disease onset, according to a recent study. The also more commonly develop primary progressive MS (PPMS). In addition, late-onset MS was associated with a higher risk of…

For people with multiple sclerosis (MS) on Ocrevus (ocrelizumab) whose disease is well controlled after at least a year of treatment, discontinuing the infusion therapy does not appear to increase the risk of new disease activity or disability progression for about two years. That’s according to a new retrospective…

A genetic variant strongly linked to Alzheimer’s disease may also worsen neurological damage in people with multiple sclerosis (MS), according to a new study. Researchers found that MS patients carrying the APOE4 variant showed greater signs of neurodegeneration than those without it, including higher levels of nerve damage biomarkers,…

Most people with multiple sclerosis (MS) have persistently high levels of antibodies against Epstein-Barr virus (EBV), but these antibodies are much less common in people with other neuroinflammatory diseases and in healthy people, a study found “This study indicates that serial testing for EBV-specific antibodies could serve as…

While many genetic factors that increase the risk of multiple sclerosis (MS) are shared across ancestral backgrounds, a study identified a variant that may reduce MS risk in South Asian people, which had not been seen in European studies — suggesting that studies focusing mainly on people of European descent…

Immunic Therapeutics has been granted a new patent in Europe covering multiple dosing regimens of its experimental therapy vidofludimus calcium and related molecules for multiple sclerosis (MS) and other indications. The patent, titled “Dosage Regimen of Vidofludimus for Use in the Treatment of a Chronic Inflammatory…

Loss of brain volume (brain atrophy), a measure often used in clinical trials to track disease progression, may not accurately reflect worsening disability in people with primary progressive multiple sclerosis (PPMS). That’s according to a new analysis of data from the Phase 3 PROMISE trial, in which measures of…